nitric oxide system is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
== Scientific research == Amarasate capsules have been clinical tested and demonstrated to reduce hunger and emptiness, to decrease food intake and to increase blood concentrations of appetite suppressing gut peptide hormones CCK, GLP-1 and PYY. Amarasate was developed on the concept that by activating bitter taste receptors (TAS2Rs), in the gastrointestinal tract, it would stimulate the release of these gut-derived hormones and potentially lead to weight loss. Clinical and laboratory research indicates that Amarasate increases GLP-1 and CCK to six times baseline levels, approximately twice the normal post-meal hormone response, within one hour of ingestion. This response mimics the body's natural satiety mechanisms without the use of external GLP-1 agonists. Three small clinical trials have been published, in normal humans:
Pedro Cuatrecasas (27 September 1936 – 19 March 2025) was a Spanish-born American biochemist and academic who was an adjunct professor of Pharmacology & Medicine at the University of California San Diego.
=== N-acetyl Modifications (NHCOH3) === Deacetylation Modifications of the N-acetyl group first involve deacetylation, which yields an amino group. Deacetylation is usually achieved by hydrazinolysis of HA using hydrazine sulfate. However, this can lead to fragmentation of the HA molecule and so, modifications for this site are not preferred.
==== Scoring systems ==== To better understand how severe cachexia is in each person, doctors use scoring systems like the Cachexia Staging Score and Cachexia Score. The Cachexia Staging Score (CSS) looks at weight loss, muscle function, appetite loss, and lab test results to categorize people into four stages: non-cachexia, pre-cachexia, cachexia, and refractory cachexia. Those in more advanced stages have less muscle mass, more frequent age-related muscle loss, worse symptoms, poorer quality of life, as well as shorter survival periods.
=== Founding === After their defeat at the convention, members of the two minority caucuses helped to found new socialist organizations. Harrington's Coalition Caucus created the Democratic Socialist Organizing Committee. The Debs Caucus, led by David McReynolds, formed the Union for Democratic Socialism. On May 30, 1973, the UDS incorporated the Socialist Party of the United States of America. Many activists from the local and state branches of the old Socialist Party of America, including the party's Wisconsin, California, Illinois, New York City, Philadelphia and Washington, D.C. organizations, participated in the reconstitution of SPUSA. After its founding, the party promoted itself as the legitimate heir of the Socialist Party of America. SPUSA elected Frank Zeidler, former Mayor of Milwaukee, as its first national chairperson. Later, SPUSA nominated Zeidler for President. Zeidler believed the party would be able to collaborate with other socialist parties nationwide to spread the message of socialism.
Sources: en.wikipedia.org
==== Alkaline phosphatase ==== Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
Antigen processing Apoptosis Biogenesis of organelles Cell cycle and division DNA transcription and repair Differentiation and development Immune response and inflammation Neural and muscular degeneration Maintenance of pluripotency Morphogenesis of neural networks Modulation of cell surface receptors, ion channels and the secretory pathway Response to stress and extracellular modulators Ribosome biogenesis Viral infection Phage defense
=== Suspension of campaign === Sanders announced that he was suspending his campaign on April 8, 2020. He stated that he would remain on the ballot in the remaining states and continue to accumulate delegates with the goal of influencing the Democratic Party's platform. On April 14, Sanders endorsed Biden. Biden responded, "I think that your endorsement means a great deal. It means a great deal to me. I think people are going to be surprised that we are apart on some issues but we're awfully close on a whole bunch of others. I'm going to need you—not just to win the campaign, but to govern."
Fostemsavir (an HIV attachment inhibitor) and lenacapavir (an HIV capsid inhibitor) are indicated in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Melarsoprol — a highly toxic antiprotozoal typically reserved for use only in late stages of the T. b. rhodesiense type of African trypanosomiasis, wherein it remains the only treatment; often results in polyneuropathy and reactive encephalopathy, resulting in death in around 5% of patients. Linezolid — used to treat drug-resistant infections of the skin and pneumonia; use is limited due to high cost and risk of vision loss or myopathy. Tigecycline — used to kill Acinetobacter and Legionella species; limited by high cost, risk of liver injury and an apparent increase in mortality.
Sources: en.wikipedia.org
Such was the likelihood of Manchester United going on to retain the title, bookmaker Fred Done paid out on punters with two months of the season left. Arsenal steadily closed the gap, however, and victory against Wimbledon in March 1998 set up a title clash between themselves and the reigning champions. Wenger in the lead up to the game maintained it was possible for Arsenal to win the league, stating "two or three weeks ago, the title was just a dream for us and people laughed when I said we could still do it". He suggested Manchester United were responsible for making the title race "interesting". At Old Trafford, Overmars scored the decisive goal to give Arsenal a 1–0 win. The victory was followed by nine consecutive league wins, the last of which was a home fixture against Everton that secured Arsenal's status as champions. Wenger became the first foreign manager to win the double, when his team beat Newcastle United in the 1998 FA Cup Final. Wenger sanctioned Wright's transfer to West Ham in the summer and made Anelka his first-choice striker ahead of the 1998–99 season. His decision not to bolster Arsenal's attack, coupled with Bergkamp's fear of flying, meant the club entered the Champions League with just one recognised striker. Their time in the competition was brief, making an exit at the group stage, with their domestic form being indifferent. Needing to strengthen their attacking options, Arsenal signed Nwankwo Kanu in January 1999, and his presence reinvigorated the team as they embarked on a run similar to last season.
The region is 1,200 kilometres (750 mi) from the sea and has an arid continental climate on the north to humid continental climate to the south, with average summer temperatures rising to 17 to 24 °C (63 to 75 °F) in July and average winter temperatures dropping to between −7 and −15 °C (19 and 5 °F) in January. Seasonal extreme temperatures can reach 39 °C (102 °F) in summer and −30 °C (−22 °F) in winter. The diurnal temperature variation can reach above 17 °C (31 °F), especially in spring. Annual rainfall averages from 190 to 700 millimetres (7.5 to 27.6 in), with more rain falling in the south of the region.
Cdc25 phosphatase catalytic domain non-catalytic domains of eukaryotic dual-specificity MAPK-phosphatases non-catalytic domains of yeast PTP-type MAPK-phosphatases non-catalytic domains of yeast Ubp4, Ubp5, Ubp7 non-catalytic domains of mammalian Ubp-Y Drosophila heat shock protein HSP-67BB several bacterial cold-shock and phage shock proteins plant senescence associated proteins catalytic and non-catalytic domains of rhodanese Rhodanese has an internal duplication. This domain is found as a single copy in other proteins, including phosphatases and ubiquitin C-terminal hydrolases. While cyanide is the most well-characterized sulfur acceptor from rhodanese, biological thiols such as glutathione are capable of acting as acceptors to form free low-molecular weight hydropersulfides such as glutathione hydropersulfide.
=== Pharmaceutical products === Several currently marketed amphetamine formulations contain both enantiomers, including those marketed under the brand names Adderall, Adderall XR, Mydayis, Adzenys ER, Adzenys XR-ODT, Dyanavel XR, Evekeo, and Evekeo ODT. Of those, Evekeo (including Evekeo ODT) is the only product containing only racemic amphetamine (as amphetamine sulfate), and is therefore the only one whose active moiety can be accurately referred to simply as "amphetamine". Dextroamphetamine, marketed under the brand names Dexedrine and Zenzedi, is the only enantiopure amphetamine product currently available. A prodrug form of dextroamphetamine, lisdexamfetamine, is also available and is marketed under the brand name Vyvanse. As it is a prodrug, lisdexamfetamine is structurally different from dextroamphetamine, and is inactive until it metabolizes into dextroamphetamine. The free base of racemic amphetamine was previously available as Benzedrine, Psychedrine, and Sympatedrine. Levoamphetamine was previously available as Cydril. Many current amphetamine pharmaceuticals are salts due to the comparatively high volatility of the free base. However, oral suspension and orally disintegrating tablet (ODT) dosage forms composed of the free base were introduced in 2015 and 2016, respectively. Some of the current brands and their generic equivalents are listed below.
In 2009 of October, Eurogentec announced the acquisition of AnaSpec, a privately owned proteomics company based in Fremont, USA. Anaspec is a provider of proteomics for life science research; they specialize in peptides synthesis, labelled peptides and antibodies, fluorescent dyes and enzyme activity assays. In 2010, Kaneka acquired a majority stake in Eurogentec S.A. Kaneka's products include synthetic resins, resin products, chemicals, foodstuffs, pharmaceuticals, medical devices, electrical raw materials and synthetic fibres. In 2012, the company started commercial manufacturing of a biopharmaceutical for USA market.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.